Report date: Nov 6,2024
Conflict count: 361874
Publisher: Ovid Technologies (Wolters Kluwer)  - Lippincott Williams & Wilkins
Title count: 161
Conflict count: 5846


==========================================================

Created: 2019-11-11 15:54:03
ConfID: 5556340
CauseID: 1458035857
OtherID: 1397564051
JT: International Clinical Psychopharmacology
MD: Hamann,18,4,237,2003,Antipsychotic prescribing patterns in Germany: a retrospective analysis using a large outpatient prescription database :
DOI: 10.1097/00004850-200307000-00006(Journal) (5556340-N)
DOI: 10.1097/01.yic.0000074989.54339.35(Journal)
==========================================================

Created: 2019-11-11 15:54:03
ConfID: 5556341
CauseID: 1458035857
OtherID: 1397564051
JT: International Clinical Psychopharmacology
MD: Grant,18,4,243,2003,Paroxetine treatment of pathological gambling: a multi-centre randomized controlled trial :
DOI: 10.1097/00004850-200307000-00007(Journal) (5556341-N)
DOI: 10.1097/01.yic.0000073881.93678.21(Journal)
==========================================================

Created: 2019-11-11 15:54:03
ConfID: 5556336
CauseID: 1458035857
OtherID: 1397564051
JT: International Clinical Psychopharmacology
MD: Feiger,18,4,203,2003,Sertraline versus fluoxetine in the treatment of major depression: a combined analysis of five double-blind comparator studies :
DOI: 10.1097/00004850-200307000-00002(Journal) (5556336-N)
DOI: 10.1097/01.yic.0000073879.27745.23(Journal)
==========================================================

Created: 2019-11-11 15:54:03
ConfID: 5556337
CauseID: 1458035857
OtherID: 1397564051
JT: International Clinical Psychopharmacology
MD: Lepola,18,4,211,2003,Escitalopram (10–20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care :
DOI: 10.1097/00004850-200307000-00003(Journal) (5556337-N)
DOI: 10.1097/01.yic.0000074988.54339.7c(Journal)
==========================================================

Created: 2019-11-11 15:54:03
ConfID: 5556338
CauseID: 1458035857
OtherID: 1397564051
JT: International Clinical Psychopharmacology
MD: Möller,18,4,219,2003,Improving the chance of recovery from the short- and long-term consequences of depression :
DOI: 10.1097/00004850-200307000-00004(Journal) (5556338-N)
DOI: 10.1097/01.yic.0000074785.11653.ca(Journal)
==========================================================

Created: 2019-11-11 15:54:03
ConfID: 5556339
CauseID: 1458035857
OtherID: 1397564051
JT: International Clinical Psychopharmacology
MD: Yatham,18,4,227,2003,Risperidone in acute and continuation treatment of mania :
DOI: 10.1097/00004850-200307000-00005(Journal) (5556339-N)
DOI: 10.1097/01.yic.0000074990.54339.e3(Journal)
==========================================================

Created: 2019-11-11 15:54:03
ConfID: 5556335
CauseID: 1458035857
OtherID: 1397564051
JT: International Clinical Psychopharmacology
MD: Brunello,18,4,191,2003,Noradrenaline in mood and anxiety disorders: basic and clinical studies :
DOI: 10.1097/00004850-200307000-00001(Journal) (5556335-N)
DOI: 10.1097/01.yic.0000073880.93678.68(Journal)